Clinical trialNCT06955169RecruitingPhase 2Interventional

Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

SponsorRTOG Foundation, Inc.Enrollment130Intracranial Meningioma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is an open-label, multicenter, randomized, phase 2 clinical study to evaluate the efficacy of \[177Lu\]Lu-DOTATATE in patients with progressive grade 1-3 intracranial meningioma.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Erik P Sulman, MD,PhD
Duke University
Principal Investigator
clinicaltrials.gov ↗
Sylvia C Kurz, MD, PhD
Yale University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of California, Irvine
Irvine, California, United States
Daniela Bota, MD, PhD
Recruiting
University of California San Diego - Moores Cancer Center
La Jolla, California, United States
Jona Hattangadi-Gluth, MD
Recruiting
Yale University
New Haven, Connecticut, United States
Sylvia Kurz, MD, PhD
Recruiting
Baptist Md Anderson Cancer Center
Jacksonville, Florida, United States
Andre Alvarez, MD PhDMichael Olson, MD PhD
Recruiting
Baptist Health Medical Group Oncology
Miami, Florida, United States
Matthew Hall, MD
Recruiting
University of Miami
Miami, Florida, United States
Marina Kushnirsky, MD
Recruiting
Moffitt Cancer Center
Tampa, Florida, United States
Andre Luiz Beer Furlan, MD, PhD
Recruiting
Piedmont Healthcare
Atlanta, Georgia, United States
Adam Nowlan, MD, MPH
Recruiting
Indiana University
Indianapolis, Indiana, United States
Kathryn Nevel, MD
Recruiting
University of Iowa Health Care
Iowa City, Iowa, United States
Kristin Plichta, MD, PhD
Recruiting
Dana-Farber/harvard Cancer Center
Boston, Massachusetts, United States
Gilbert Youssef, MD
Recruiting
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, United States
Sean Miller, MD
Recruiting
Henry Ford Hospital
Detroit, Michigan, United States
Tobias Walber, MD, PhD, MPH
Recruiting
Nyu Lagone Health
New York, New York, United States
Marissa Barbaro, MD
Recruiting
Duke University Medical Center
Durham, North Carolina, United States
Margaret Johnson, MD
Recruiting
Md Anderson Cancer Center
Houston, Texas, United States
Carlos Kamiya-Matsuoka, MD
Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Michael Straza, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Dotatate →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 24 Aug 2025
Primary completion: 31 Aug 2029
Completion: 31 Aug 2030
Last update posted: 2 Oct 2026
Registered enrollment: 130
Registry id: NCT06955169

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.